Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TP-317 by Thetis Pharmaceuticals for Inflammatory Bowel Disease: Likelihood of Approval
TP-317 is under clinical development by Thetis Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData,...